Premium
KHA‐CARI Guideline: Use of iron in chronic kidney disease patients
Author(s) -
MacGinley Rob,
Walker Rowan,
Irving Michelle
Publication year - 2013
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12139
Subject(s) - rowan , medicine , guideline , library science , citation , family medicine , pathology , ecology , computer science , biology
a. That therapeutic iron be used to correct diagnosed iron deficiency (1D). b. Parenteral iron (intravenous) is administered in preference to oral iron to correct iron deficiency. As it is more likely to: • achieve target haemoglobin (Hb) levels (1B), • maintain ferritin and transferrin saturation (%TSAT) at target ranges (1C), • reduce erythropoiesis stimulating agent (ESA) dose requirements (1C) and • have fewer adverse reactions (1C).